Efficacy of low-dose valganciclovir in CMV R+ lung transplant recipients: a retrospective comparative analysis

BACKGROUND: Cytomegalovirus (CMV) infection is extremely common after lung transplant and can be associated with significant morbidity and mortality. Current practice suggests the use of 900 mg daily of valganciclovir for CMV prophylaxis, but there is no literature assessing whether 450 mg daily of...

Descripción completa

Detalles Bibliográficos
Autores principales: Hunt, Jessica, Chapple, Kristina M., Nasar, Aasya, Cherrier, Lauren, Walia, Rajat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: PAGEPress Publications, Pavia, Italy 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868948/
https://www.ncbi.nlm.nih.gov/pubmed/33569173
http://dx.doi.org/10.4081/mrm.2021.706

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868948/
https://www.ncbi.nlm.nih.gov/pubmed/33569173
http://dx.doi.org/10.4081/mrm.2021.706

Ejemplares similares